Viatris Inc., a global healthcare company, has acquired Aculys Pharma Inc., a clinical stage biopharmaceutical company focused on commercializing innovative treatments for neurological conditions. As part of the transaction, Viatris has acquired exclusive development and commercialization rights in Japan for pitolisant, a selective/inverse agonist of the histamine H3 receptor. Based on the strength of recent Phase 3 clinical trial results in Japanese patients and the positive benefit-risk pro...